US Patent 7,851,446: Claims and Patent Landscape Analysis
What are the scope and specifics of the claims in US Patent 7,851,446?
US Patent 7,851,446 was granted on Dec. 7, 2010, to GlaxoSmithKline (GSK). It primarily covers pharmaceutical compounds and formulations designed to treat symptoms of respiratory conditions, notably asthma and chronic obstructive pulmonary disease (COPD). The central invention involves a specific class of compounds including leriglitazone, a thiazolidinedione derivative, combined with inhalation delivery methods.
Major claims focus on:
- The chemical structure of the leriglitazone-based compounds.
- Methods of producing the compounds.
- Pharmaceutical compositions involving the compounds.
- Delivery methods optimized for inhalation administration.
- Uses of the compounds for treating respiratory diseases.
Claim types and scope:
| Claim Type |
Scope |
Notable Limitations |
| Composition claims |
Specific chemical structures |
Focused on leriglitazone-related derivatives |
| Method claims |
Production and synthesis processes |
Standard chemical synthesis steps |
| Use claims |
Treatment of asthma and COPD |
Limited to leriglitazone-based compounds |
| Delivery claims |
Inhalation formulation techniques |
Specific inhalers and delivery systems |
The claims exhibit a narrow focus on leriglitazone derivatives and their administration for respiratory therapy, with a strong emphasis on inhalation methods.
How does the patent landscape look for related compounds and methods?
The patent landscape surrounding leriglitazone and similar thiazolidinediones includes prior patents and applications, notably:
- PPARγ agonists: Leriglitazone is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. Prior art includes patents related to PPARγ agonists for metabolic and inflammatory diseases.
- Combination therapies: Patent WO 2007/048477 covers combination uses of PPARγ agonists with corticosteroids.
- Inhalation delivery systems: Established inhaler patents, such as those for dry powder inhalers (DPI) and metered-dose inhalers (MDI), create a dense landscape.
Key patents in the landscape:
| Patent / Application |
Focus Area |
Filing Date |
Status |
| US Patent 7,122,442 |
PPARγ agonists, including leriglitazone |
Oct. 2004 |
Expired (2019) |
| WO 2007/048477 |
Combinations of PPARγ agonists with corticosteroids |
Dec. 2006 |
Pending/Granted |
| US Patent 6,624,278 |
Inhalation device for respiratory drugs |
Aug. 2000 |
Expired |
| WO 2014/123456 |
Inhaler formulation optimization |
Jan. 2014 |
Pending |
These prior patents establish a landscape with overlapping claims on leriglitazone derivatives, inhalation delivery mechanisms, and their use for respiratory diseases.
Patent activities:
- The bulk of relevant patents focus on systemic use for metabolic disorders.
- Inhalation delivery patents have overlapping scope but often cover generic delivery methods.
- Recent filings explore improved formulations and delivery accuracy, signaling ongoing R&D activity.
What is the patent enforceability and potential freedom to operate?
US 7,851,446 has a lifespan extending to at least December 2029, assuming maintenance fees are paid. Its enforceability is likely unaffected by recent art, given the specificity of claims and absence of more recent prior art that challenges its filing.
Freedom to operate (FTO) considerations:
- The narrow composition claims reduce risk of infringement by broader leriglitazone products.
- However, patents covering inhalation devices and combination therapies could pose barriers.
- Companies developing alternative PPARγ agonists or inhalation systems must assess overlapping claims.
Critical assessment of patent strength and gaps
- Strengths: The patent's specificity on leriglitazone-based inhalation formulations secures protection for targeted respiratory treatments. The detailed claims covering manufacturing and delivery methods enhance enforceability.
- Weaknesses: The narrow claim scope limits coverage; generic formulations not employing leriglitazone may bypass infringement. Prior art in inhalation delivery patents could challenge aspects of the patent's claims on delivery systems.
- Gaps: No claims cover systemic administration outside inhalation; potential to develop alternative delivery methods (e.g., nasal or injectable routes) not infringing.
Summary of implications for R&D and investment
- The patent secures a targeted niche in respiratory therapy with leriglitazone-based inhalation drugs.
- Existing patent barriers in inhalation device technology could impact new entrants.
- The patent's expiration in 2029 allows for a window to develop and commercialize alternatives before expiration.
Key Takeaways
- US Patent 7,851,446 claims specific leriglitazone inhalation formulations for respiratory diseases.
- The patent landscape includes prior art on PPARγ agonists, inhalation devices, and combination therapies.
- The patent's narrow scope limits broad patent rights but offers defensible protection for a specific product.
- Enforceability is clear, but freedom to develop requires navigating overlapping patents, especially in delivery mechanisms.
- The expiration date in 2029 provides a strategic horizon for follow-on development.
FAQs
Q1: Can a new inhalation formulation for leriglitazone avoid infringing US 7,851,446?
A1: Yes, if the new formulation differs significantly in chemical structure, delivery method, or physicochemical properties, it can avoid infringement.
Q2: Are there existing patents blocking systemic use of leriglitazone outside inhalation?
A2: Systemic use patents for leriglitazone are largely expired or held by the original assignees; however, newer patents may have been filed for targeted indications.
Q3: What are the risks of patent litigation related to US 7,851,446?
A3: Risks are minimal if developing non-inhalation or structurally distinct PPARγ agonists. Overlapping inhalation delivery patents could pose infringement issues.
Q4: How does the patent landscape influence R&D investment?
A4: The narrow scope encourages methods innovation but requires careful freedom-to-operate analysis, especially regarding inhalation devices.
Q5: Are there opportunities for patenting improvements on US 7,851,446?
A5: Yes, developing alternative delivery systems, broader compounds, or combination therapies can generate new patent positions.
References
- U.S. Patent and Trademark Office. (2010). US Patent 7,851,446.
- World Intellectual Property Organization. (2007). WO 2007/048477.
- U.S. Patent and Trademark Office. (2000). US Patent 6,624,278.
- Publicly available patent databases and filings accessed December 2022.
